PDE4A and psoriatic arthritis: Apremilast is a phosphodiesterase 4 (PDE4) inhibitor that has been Food and Drug Administration (FDA) approved for psoriasis, psoriatic arthritis, and oral ulcers associated with Behcet's disease; apremilast has also shown promise off-label for other inflammatory skin conditions.